Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News
Bioniche on List for Second Year
Bioniche Life Sciences Inc. announced that it has been recognized as one of the top 100 global biotechnology companies by Med Ad News in its 13th annual report released in the magazine's July, 2004 issue. Bioniche placed 41st in Revenue (51st in 2002); 82nd in Research and Development (81st in 2002); and 40th in Employees (48th in 2002). Bioniche is one of only seven Canadian companies to be included in the report.
Eligibility requirements for the Med Ad News biotechnology report include being publicly-traded; research and development of human therapeutics deriving from a naturally-occurring substance or a biological substance - either human, animal, or plant; applying genetic engineering or recombinant DNA technology; and having therapeutic products intended for sale through prescription.
Graeme McRae, President and CEO of Bioniche Life Sciences, commented, "Bioniche's inclusion in this prestigious listing for the second year is evidence of our success in building an established and rapidly growing global healthcare company. Our 25 years of research and development have yielded groundbreaking platform technologies to address worldwide needs in both the human and animal health fields. Our production and marketing capacities have driven market penetration in our product categories and our revenue base continues to expand.
"Our strategic goals for the coming year include initiating the late stage clinical trial of an effective treatment for bladder cancer, and the approval of a vaccine to prevent E. coli O157:H7 contamination of food and water. We continue to move our extensive pipeline of proprietary research forward and develop additional revenue streams for the future."
The recognition of Bioniche by Med Ad News comes on the heels of the Company's 88th place ranking among Canada's 100 fastest-growing companies by PROFIT: Your Guide to Business Success, announced in June of this year.
Other news from the department business & finance
